Llwytho...
Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
Background: Transthyretin amyloid cardiomyopathy is a progressive disease with a poor prognosis. There had been no specific treatment for transthyretin amyloid cardiomyopathy until tafamidis received expanded approval in March 2019 in Japan. However, the clinical efficacy of tafamidis remains unknow...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Circ Rep |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
The Japanese Circulation Society
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7819654/ https://ncbi.nlm.nih.gov/pubmed/33693263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1253/circrep.CR-20-0062 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|